Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity.

Naoe Y, Inami M, Kawamura I, Nishigaki F, Tsujimoto S, Matsumoto S, Manda T, Shimomura K.

Jpn J Cancer Res. 1998 Jun;89(6):666-72.

PMID:
9703365
2.

The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.

Fourie J, Oleschuk CJ, Guziec F Jr, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.

Cancer Chemother Pharmacol. 2002 Feb;49(2):101-10.

PMID:
11862423
3.

FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.

Naoe Y, Inami M, Matsumoto S, Takagaki S, Fujiwara T, Yamazaki S, Kawamura I, Nishigaki F, Tsujimoto S, Manda T, Shimomura K.

Jpn J Cancer Res. 1998 Dec;89(12):1306-17.

PMID:
10081492
4.

Interstrand cross-linking of DNA by FK317 and its deacetylated metabolites FR70496 and FR157471.

Williams RM, Ducept P.

Biochemistry. 2003 Dec 16;42(49):14696-701.

PMID:
14661983
5.

Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.

Bailey SM, Wyatt MD, Friedlos F, Hartley JA, Knox RJ, Lewis AD, Workman P.

Br J Cancer. 1997;76(12):1596-603.

6.

Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions.

Shibata K, Kasahara K, Bando T, Nakatsumi Y, Fujimura M, Tsuruo T, Matsuda T.

Jpn J Cancer Res. 1995 May;86(5):460-9.

PMID:
7790319
7.

Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.

Singh SV, Xu BH, Gupta V, Emerson EO, Zaren HA, Jani JP.

Cancer Lett. 1995 Aug 16;95(1-2):49-56.

PMID:
7656243
8.

Interactions of mitomycin C with mammalian DNA detected by alkaline elution.

Dorr RT, Bowden GT, Alberts DS, Liddil JD.

Cancer Res. 1985 Aug;45(8):3510-6.

9.

Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.

Lee JH, Naito M, Nakajima M, Tsuruo T.

Cancer Chemother Pharmacol. 1993;33(3):215-20.

PMID:
7505723
11.

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA, Pommier Y.

Mol Pharmacol. 1999 Sep;56(3):478-84.

12.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.

Cancer Res. 2004 Sep 15;64(18):6693-9.

13.

Cellular pharmacology of polynuclear platinum anti-cancer agents.

Roberts JD, Peroutka J, Farrell N.

J Inorg Biochem. 1999 Oct;77(1-2):51-7.

PMID:
10626354
14.

DNA damage, cytotoxicity and free radical formation by mitomycin C in human cells.

Dusre L, Covey JM, Collins C, Sinha BK.

Chem Biol Interact. 1989;71(1):63-78.

PMID:
2550152
15.

Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.

Fourie J, Guziec F Jr, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A.

Cancer Chemother Pharmacol. 2004 Mar;53(3):191-203.

PMID:
14614574
16.

Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.

Bando T, Kasahara K, Shibata K, Numata Y, Heki U, Shirasaki H, Iwasa K, Fujimura M, Matsuda T.

J Cancer Res Clin Oncol. 1996;122(1):21-6.

PMID:
8543588
17.

FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo.

Beckerbauer L, Tepe JJ, Cullison J, Reeves R, Williams RM.

Chem Biol. 2000 Oct;7(10):805-12.

18.

Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells.

Masuda K, Nakamura T, Shimomura K.

Jpn J Pharmacol. 1990 Aug;53(4):463-72.

19.

Interstrand DNA-DNA and DNA-protein cross-links by a new antitumor antibiotic, FK973, in L1210 cells.

Masuda K, Nakamura T, Mizota T, Mori J, Shimomura K.

Cancer Res. 1988 Sep 15;48(18):5172-7.

20.

DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.

Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T.

Cancer Res. 1996 Jun 15;56(12):2823-6.

Items per page

Supplemental Content

Support Center